openPR Logo
Press release

North America To Dominate Global Human Chorionic Gonadotropin (HCG) Market, Owing To Rising Frequency Of Infertility Cases

03-27-2018 01:39 PM CET | Health & Medicine

Press release from: Pharmaceutical Report By CMI

North America To Dominate Global Human Chorionic Gonadotropin

North America to dominate global human chorionic gonadotropin (HCG) market, owing to rising frequency of infertility cases

On the basis of geography, the global human chorionic gonadotropin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is the highest regional contributor to the market and is expected to continue as a regional dominator over the forecast years. This primarily owes to the rising number of infertility cases as well as hormonal dysfunction among young males and females as a result of changing lifestyle. According to Mayo Clinic, around 25% of women fertility problems in the U.S. are a result of ovulation issues that are mostly caused due to dysfunction of human chorionic gonadotropin (HCG) hormone. Thus, the rapidly increasing cases of infertility are expected to surge the North America global human chorionic gonadotropin market. On the other hand, Asia Pacific is anticipated to be the fasting growing geography, owing to economic developments facilitating technological advancements in healthcare sectors as well as emerging local players in the market.

The key players operating the global human chorionic gonadotropin market include Merck & Co., Inc., EMD Sereno, Inc., Fresenius Kabi, Bristol Myers Squibb Company, Ferring BV, and Kamia Biomedical Company. Acris Antibodies developed a human chorionic gonadotropin hormone by recombinant DNA technology that helps to prevent the disintegration of the corpus luteum of the ovary thereby, maintaining levels of progesterone production for healthy pregnancy in females.

Human chorionic gonadotropin hormone (HCG) is a hormone secreted by the placenta after implantation of a fertilized zygote in the uterus. The hormone also supports normal development of an egg and helps in the stimulation of egg release from the ovary. The HCG is mainly used to induce ovulation in the women under infertility treatment. It is also used among males mostly to increase the sperm count and in young boys, due to pituitary gland disorders and other diseases, due to which the testicles of the young males does not drop down naturally into the scrotum. The HCG is usually administered as an injection under the skin into a muscle. The HCG can also be administered at home under the advice of a gynecologist or a pharmacist. The HCG levels can be determined with the help of urine or blood test. Result of specific test helps in the determining accurate measurement of the levels. These tests are mostly used to identify and confirm pregnancy or as a screening test to determine birth defects.

Get The Holistic SAMPLE With TOC:
https://www.coherentmarketinsights.com/insight/request-sample/1011

Rising incidence of infertility are expected to drive the growth of human gonadotropin market across the globe

According to Centers of Disease Control and Prevention (CDC) in 2016, approximately 7.3 million women aged 15 - 44 have used infertility services. Moreover, 6.7% of the married women aged 15 - 44 were reported infertile. According to Azura Vascular Care, around 17% of the couples in the U.S. deal with infertility out of which 30% cases are a result of male infertility. These numbers suggests significant demand for infertility treatments, such as HCG in order for females to conceive a child. According to a statistical survey conducted by HealthGrove, pituitary gland disorders resulted into the death of around 205 people in 2015, out of which highest percentage belonged to white men. Pituitary disorders resulting into significant mortality rate are propelling the demand for human chorionic gonadotropin hormone. Additionally, various other factors such as endometriosis, hormonal imbalance, polycystic ovary syndrome, and others are expected to propel the growth of global HCG market. For instance, according to Frisco Institute of Reproductive Medicine, around 10% of women of reproductive age in the U.S. suffer from polycystic ovary syndrome. However, easy availability of alternatives to treat infertility could act as potential barriers for the market growth.

Market Taxonomy:

The global human chorionic gonadotropin by Coherent Market Insights is segmented on the basis of Technology, Therapeutic area, and end user.

On the basis of technology, the global human chorionic gonadotropin is segmented as:

Natural Source Extraction
Recombinant DNA Technology
On the basis of therapeutic area, the global human chorionic gonadotropin market is segmented as:

Female infertility treatment
Oligospermic Treatment
Cryptorchidism Treatment
Others
On the basis of end user, the global human chorionic gonadotropin market is segmented as:

Fertility Centers
Research Institutes
Others

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release North America To Dominate Global Human Chorionic Gonadotropin (HCG) Market, Owing To Rising Frequency Of Infertility Cases here

News-ID: 994372 • Views: 309

More Releases from Pharmaceutical Report By CMI

Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the

All 5 Releases


More Releases for HCG

Add hCG to a Medical Practice in 2013: Attend the IAPAM's January 25 hCG Trainin …
Las Vegas, Nevada, USA - January 9, 2013 -- In 2012, there was unprecedented positive interest in hCG for weight loss. To meet the ongoing consumer demand for the hCG diet in 2013, the IAPAM is helping physicians enter this lucrative, cash-based market, by offering their NEW and IMPROVED physician-led Clean Start hCG Training in Scottsdale, Arizona on January 25, 2013. Physicians will learn and receive everything they need to
Physicians Certified at the IAPAM's hCG Training are True hCG Experts
Las Vegas, Nevada, USA - June 8, 2012 -- The IAPAM is committed to educating physicians in the industry’s best practices for hCG for weight loss. The scope of the IAPAM's hCG Training ensures that physicians who graduate have unsurpassed clinical and business knowledge on hCG and medical weight management. Attendees receive all the tools needed to launch an hCG diet program, and graduates of the IAPAM's hCG Training are
07-25-2011 | Health & Medicine
IAPAM
Graduates of the IAPAM's hCG Training are True hCG Experts
The IAPAM is committed to educating physicians in the industry’s best practices for hCG for weight loss. The scope of the IAPAM's hCG Training ensures that physicians who graduate have unsurpassed clinical and business knowledge on hCG and medical weight management. Attendees receive all the tools needed to launch an hCG for weight loss program, and graduates of the IAPAM's hCG Training are launching the most successful hCG Clinics in
Graduates of the IAPAM's hCG Training are True hCG Experts
The IAPAM is committed to educating physicians in the industry’s best practices for hCG for weight loss. The scope of the IAPAM's hCG Training ensures that physicians who graduate have unsurpassed clinical and business knowledge on hCG and medical weight management. Attendees receive all the tools needed to launch an hCG for weight loss program, and graduates of the IAPAM's hCG Training are launching the most successful hCG Clinics in
Glenmore Healthcare's hCG Program is Consistent with Dr. Oz's hCG Principles
Calgary, Alberta, June 30, 2011 -- The core principles of Glenmore Healthcare's hCG for Weight Loss Program are consistent with those outlined by Dr. Oz in his interview for First for Women magazine's June 27th issue: it is imperative for patients to undertake an hCG program under the care of a trained physician, and never use hCG (homeopathic hCG) that is sold without a prescription. In his recent interview in the
IAPAM's hCG Directory Helps Consumers Find Expert hCG Physicians
The International Association for Physicians in Aesthetic Medicine offers patients a NEW hCG Diet Clinic listing of physicians in their area, who have been expertly trained in hCG for weight loss by the IAPAM. Las Vegas, NV, May 17, 2011 -- The IAPAM's NEW hCG Diet Listing (http://www.iapam.com/aesthetic-resources/hcg-diet-clinics) provides consumers with a comprehensive listing of qualified IAPAM trained hCG Physicians. Patients seeking out certified physicians, who have completed the IAPAM’s hCG